CompletedNCT01682161
A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
Medication studyAges 20–65South KoreaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 20 years to 65 years.
- Listed locations
- Buchun and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJanuary 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 154
- Sponsor
- Janssen Korea, Ltd., Korea
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 20 Years to 65 Years
- Official registry ID
- NCT01682161
- Official title
Show the full official title
An Open-Label, Comparative Study of Immediate or Delayed Switch to Paliperidone Palmitate in Patients Unsatisfied With Current Oral Atypical Antipsychotics to Evaluate the Evolution of Medication Satisfaction and Adherence
Get this study by email
Recruitment & locations
CompletedBuchun · Cheonan · Chungcheongbuk-Do
6 more locations
- Daegu
- Goyang
- Gyeonggi-do
- Incheon
- Seognam-Si, Kyungki-Do
- Seoul
Questions about this study
Who is behind this study?
The study sponsor is Janssen Korea, Ltd., Korea.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone palmitate.
Who was this study for?
Listed age limits: 20 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia